

Summary of Safety and Effectiveness
Liquichek™ D-dimer Control

FEB 24 2003

1.0 **Submitter**

Bio-Rad Laboratories
9500 Jeronimo Road,
Irvine, California 92618-2017
Telephone: (949) 598-1200
Fax: (949) 598-1555

Contact Person

Maria Zeballos
Regulatory Affairs Specialist
Telephone: (949) 598-1367

Date of Summary Preparation

January 15, 2003

2.0 **Device Identification**

Product Trade Name: Liquichek™ D-dimer Control
Common Name: Plasma, Coagulation Control

Classifications: Class II
Product Code: GGN
Regulation Number: CFR 862.5425

3.0 **Device to Which Substantial Equivalence is Claimed**

STAGO Diagnostica
STA-Liatest® Control [N]+[P]
Parsippany, New Jersey 07504

Docket Number: K964716

4.0 **Description of Device**

Liquichek™ D-dimer Control is prepared from processed human plasma with added constituents of human and animal origin, and preservatives. The control is provided in liquid form for convenience.

5.0 Statement of Intended Use

Liquichek™ D-dimer Control is intended for use as an assayed quality control to monitor the precision of laboratory testing procedures for D-dimer.

6.0 Comparison of the new device with the Predicate Device

The Liquichek™ D-dimer Control claims substantial equivalence to the STAGO STA® - Liatest Control [N] + [P] currently in commercial distribution (K964716).

Table 1. Similarities and Differences between new and predicate device.

Characteristics	Bio-Rad Liquichek™ D-dimer Control (New Device)	STAGO Diagnostica STA-Liatest® Control [N] + [P] (Predicate Device K964716)
Similarities		
Intended Use	Liquichek D-dimer Control is intended for use as a quality control to monitor the precision of D-dimer procedures.	The STA-Liatest® Control [N]+[P] kit is intended for use as control plasmas (normal and abnormal levels) for intended use: von Willebrand Factor (vWF), free protein S and D-dimer assays on STA® analyzers by the immuno-turbidimetric method.
Levels	Level 1 and Level 2	Normal and abnormal levels
Analytes	D-dimer	D-dimer [Von Willebrand Factor (vWF), free protein S are also in the controls]
Storage (Unopened)	2°C to 8°C Until expiration date	2°C to 8°C Until expiration date
Differences		
Open Vial Claim	30 days at 2 to 25°C	8 hours at 15 to 20°C
Matrix	Processed human plasma with added constituents of human and animal origin, and preservatives.	Citrated normal or abnormal plasma.
Form	Liquid	Freeze-dried

7.0 STATEMENT OF SUPPORTING DATA

Stability studies have been performed to determine the open vial stability and shelf life for the Liquichek™ D-dimer Control. Product claims are as follows:

7.1 Open vial: Once the product is opened, the analyte will be stable for 30 days when stored tightly capped at 2 to 25°C.

7.2 Shelf Life: Three years when stored at 2 to 8 °C.

Real time studies will be ongoing to support the shelf life of this product.

All supporting data is retained on file at Bio-Rad Laboratories.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Food and Drug Administration
2098 Gaither Road
Rockville MD 20850

FEB 24 2003

Ms. Maria Zeballos, RAC
Regulatory Affairs Specialist
Bio-Rad Laboratories, QSD
9500 Jeronimo Road
Irvine, CA 92618

Re: k030182
Trade/Device Name: Liquichek™ D-dimer Control
Regulation Number: 21 CFR 864.7320
Regulation Name: Fibrinogen/fibrin degradation products assay
Regulatory Class: Class II
Product Code: DAP; GGN
Dated: February 4, 2003
Received: February 5, 2003

Dear Ms. Zeballos:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (301) 594-3084. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink that reads "Steven Gutman". The signature is written in a cursive, slightly slanted style.

Steven I. Gutman, M.D., M.B.A.
Director
Office of *In Vitro* Diagnostic Device
Evaluation and Safety
Center for Devices and
Radiological Health

Enclosure

510 (k) Number (if known): K030182

Device Name: **Liquichek™ D-dimer Control**

Indications for Use:

Liquichek D-dimer Control is intended for use as an assayed quality control to monitor the precision of laboratory testing procedures for D-dimer.


Methods:

- bioMerieux Vidas
- Dade Behring BCS/BCT – Advanced D-Dimer
- Dade Behring Stratus CS
- Dade Behring Sysmex Series – Advanced D-Dimer
- Diagnostica Stago Sta/Sta-R/Sta-Compact – LIATEST
- IL ACL Series
- Roche Cobas Integra 400/800 – Tina-quant
- Roche Hitachi – Tina-quant

(PLEASE DO NOT WRITE BELOW THE LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Prescription use ✓ or Over-the Counter use _____


(Division Sign-Off)
Division of Clinical Laboratory Devices

510(k) Number K030182